These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 29501721)

  • 1. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
    Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
    J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ligand-targeted liposomes for cancer therapy.
    Noble CO; Kirpotin DB; Hayes ME; Mamot C; Hong K; Park JW; Benz CC; Marks JD; Drummond DC
    Expert Opin Ther Targets; 2004 Aug; 8(4):335-53. PubMed ID: 15268628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery.
    Kuang H; Ku SH; Kokkoli E
    Adv Drug Deliv Rev; 2017 Feb; 110-111():80-101. PubMed ID: 27539561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-targeted liposomes for cancer treatment.
    Sapra P; Tyagi P; Allen TM
    Curr Drug Deliv; 2005 Oct; 2(4):369-81. PubMed ID: 16305440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
    Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
    Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-functionalized liposomes for targeted cancer therapy.
    Moosavian SA; Sahebkar A
    Cancer Lett; 2019 Apr; 448():144-154. PubMed ID: 30763718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-targeted liposome design: challenges and fundamental considerations.
    Noble GT; Stefanick JF; Ashley JD; Kiziltepe T; Bilgicer B
    Trends Biotechnol; 2014 Jan; 32(1):32-45. PubMed ID: 24210498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
    Maruyama K
    Adv Drug Deliv Rev; 2011 Mar; 63(3):161-9. PubMed ID: 20869415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity.
    Liao D; Liu Z; Wrasidlo W; Chen T; Luo Y; Xiang R; Reisfeld RA
    Nanomedicine; 2011 Dec; 7(6):665-73. PubMed ID: 21419870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors.
    Dicheva BM; Koning GA
    Expert Opin Drug Deliv; 2014 Jan; 11(1):83-100. PubMed ID: 24320104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome targeting to tumors using vitamin and growth factor receptors.
    Drummond DC; Hong K; Park JW; Benz CC; Kirpotin DB
    Vitam Horm; 2000; 60():285-332. PubMed ID: 11037627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-targeted liposomal anticancer drugs.
    Sapra P; Allen TM
    Prog Lipid Res; 2003 Sep; 42(5):439-62. PubMed ID: 12814645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity.
    Stefanick JF; Omstead DT; Kiziltepe T; Bilgicer B
    Nanoscale; 2019 Mar; 11(10):4414-4427. PubMed ID: 30801591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy.
    Moosavian SA; Bianconi V; Pirro M; Sahebkar A
    Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Tumor Targeted Liposomes.
    Jain A; Jain
    Curr Mol Med; 2018; 18(1):44-57. PubMed ID: 29663884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.